3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
16
Neoplasms
6
Colorectal Neoplasms
5
Solid Tumors
3
Urinary Bladder Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Noonan Syndrome
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Lung Diseases
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Interventions
Carboplatin
8
Paclitaxel
7
Gemcitabine
7
Irinotecan
6
Radiotherapy
4
Oxaliplatin
4
Capecitabine
4
Leucovorin
3
Fluorouracil
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Trastuzumab
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Etoposide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tipifarnib
1
tegafur-gimeracil-oteracil
1
sintilimab
1
pertuzumab
1
pemigatinib
1
pembrolizumab
1
olaparib
1
ivosidenib
1
ipatasertib
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Unknown Primary
×
cobimetinib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts